San Francisco, 25
September 2018: The global oncology
based in-vivo CRO market is expected to reach USD 1.5 billion by 2025,
according to a new report by Grand View Research, Inc. The use of Contract
Research Organization (CRO) oncology services helps the manufacturers/sponsors
to provide complete attention on the production capacity and at enhancing their
in-house processes.
Furthermore, the pressure from the increasing competition
due to patent expirations, rapid growth of generics, and introduction of
biosimilar equivalents are propelling the pharmaceutical companies to take the
aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO
market may witness lucrative growth over the forecast period.
Another factor propelling growth is the
increasing incidence of cancer, and high failure rate of existing treatment
options. According to statistics published by the World Health Organization
(WHO), approximately 8.2 million deaths are recorded each year from cancer,
which accounts for 13.0% deaths worldwide.
Access
Research Report of Oncology Based In-vivo
CRO Market @ www.grandviewresearch.com/industry-analysis/oncology-based-in-vivo-cro-market
Further key findings from the study suggest:
· Based on indication, solid tumors are
expected to dominate the market as of 2016. Furthermore, it is anticipated to
grow at the fastest CAGR owing to the factors such as growing incidence rate,
augmenting research for tumors in organs such as breast, and liver, and
technological advancement offered by key industry players.
· Solid tumors are analyzed by means of
models such as xenograft, Patient Derived Xenografts (PDX), and syngeneic. The
PDX models are expected to witness lucrative growth over the forecast period
and capture over 40.0% of the market share by 2025.
· Geographic expansion into Asia Pacific
countries by well-established players is anticipated to promote the fastest
growth for the region. India is one the most lucrative country owing to
presence of service tax exemption and venture capital based funding for CROs.
· Few of the industry players for the
oncology based in-vivo CRO market are The Jackson
Laboratory, Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC,
Wuxi AppTec, and ICON Plc.
· A common trend observed is the rising
partnerships among CROs to offer bundle packages of services to sponsors. For
instance, In May 2017, CRL International, Inc. announced their partnership with
OcellO, established in Netherlands. According to this partnership, CRL would be
utilizing the latter’s PDX model capabilities in order to expand their oncology
based drug discovery service portfolio.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has segmented the global oncology
based in-vivo CRO
market on the basis of indication, and region:
Global Oncology Product Outlook (Revenue,
USD Million, 2014 - 2025)
·
Blood cancer
·
Solid tumors
o
Syngeneic model
o
Patient Derived Xenograft (PDX)
o
Xenograft
·
Others
Oncology in-vivo CRO Regional Outlook (Revenue, USD Million, 2014 -
2025)
·
North America
o
U.S.
o
Canada
·
Europe
o
UK
o
Germany
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Argentina
·
Middle East and Africa (MEA)
o
South Africa
o
Saudi Arabia
Access Press Release of
Oncology Based In-vivo CRO Market@ www.grandviewresearch.com/press-release/global-oncology-based-in-vivo-cro-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research reports, and consulting services. To help
clients make informed business decisions,
we offer market intelligence studies ensuring relevant and fact-based research
across a range of industries, from technology to chemicals, materials and
healthcare.
